Yazar "Dede, Bülent" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    A novel schiff base derivative for effective treatment of azoxymethane induced colon cancer
    (IJPSR, 2014) Doğan, Ayşegül; Başak, Neşe; Demirci, Selami; Telci, Dilek; Dede, Bülent; Tuzcu, Mehmet; Özercan, İbrahim Halil; Şahin, Kazım; Şahin, Fikrettin
    The field of cancer research has been emerged in recent years for the development of specific drugs to cancer treatment. New agents with the ability to provide efficient treatment by reducing side effects has led to new opportunities for improving agents for cytotoxic therapies. While there are several drugs for colon cancer treatment, researchers are trying to evaluate new agents or combinations of existing ones which can be used efficiently. Schiff bases with a wide range of variety and biological properties including anticancer activity might be used for colon cancer treatment. In the current study, a novel schiff base derivative synthesized by our group was tested in vivo for colon cancer. In a model of azoxymethane (AOM) induced colorectal cancer, chemopreventive properties of schiff base was also analyzed in rats. While AOM induced de novo crypt formation, adenocarcinoma and dysplasia development, schiff base application reduced the number of aberrant crypt foci (ACF), dysplasia or adenocarcinoma. Analysis of the intestinal mucosa showed that peritoneal administration of SB complex not only decreased the protein expression of COX-2, Bcl-2 and NF-κB but also enhanced the Bax expression suggesting the apoptotic and anti-proliferative effects for this compound. Our findings showed that SB complex might be used for the colorectal cancer treatment. Further studies are highly warranted to obtain additional insights and identify mode of action for the schiff base.
  • Küçük Resim Yok
    Öğe
    A Schiff base derivative for effective treatment of diethylnitrosamine induced liver cancer in vivo
    (Anticancer Drugs, 2015) Demirci, Selami; Doğan, Ayşegül; Başak, Neşe; Dede, Bülent; Telci, Dilek; Orhan, Cemal; Tuzcu, Mehmet; Şahin, Kazım; Şahin, Nurhan; Özercan, İbrahim; Şahin, Fikrettin
    Hepatocellular carcinoma is one of the most prevalent cancers, with a high morbidity rate, even in developed countries. In the present study, the curative effect of the Schiff base (SB) heterodinuclear copper(II)Mn(II) complex on diethylnitrosamine (DEN)-induced liver carcinoma was investigated. Hepatocarcinoma was initiated by an injection of DEN and promoted by phenobarbital (0.05%) in the diet. In addition, the potential nephrotoxicity of SB was evaluated in a cisplatin-induced nephrotoxicity model. Rats were administered the SB complex (1 and 2 mg/kg body weight/day) for 24 weeks, and cancer progression was investigated by macroscopic, histopathological, and western blot examinations. The administration of SB decreased the incidence and the number of hepatic nodules in a dose-dependent manner by regulating inflammation response and the apoptotic pathway. Western blot analyses from the livers of rats treated with SB after DEN induction showed significantly enhanced Bax and caspase-3 levels, with a marked decrease in the levels of Bcl-2, NF-κB p65 and cyclooxygenase (COX)-2. Results from the nephrotoxicity study showed that, whereas cisplatin increased serum urea nitrogen and creatinine levels, no increase in serum biochemical parameters was detected in SB-treated animals. Moreover, protein levels of NF-E2-related factor-2 (Nrf2) and heme oxygenase-1 were lower, whereas nuclear factor-κB (NF-κB p65) and activator protein-1 levels were higher in the kidneys of cisplatin-treated animals compared with that of the SB groups. Therefore, the SB complex could be an alternative chemotherapeutic option for liver cancer treatment once its safety in clinical applications has been examined.